Bank of America spends more than $250 million annually on GLP-1 weight-loss drugs for its workforce, CEO Brian Moynihan confirmed on Aug. 5, 2026, during an interview at the Aspen Economic Strategy Group annual meeting. The expenditure represents 13% of the bank’s $2 billion annual healthcare budget for its 211,000 employees, up from zero spending on these medications just four or five years ago.
Moynihan described the investment as a worthwhile benefit, citing short- and long-term health improvements for employees, including potential reductions in cardiovascular risks. The bank pairs drug coverage with health coaching to support lifestyle changes. Bank of America is also negotiating aggressively for lower prices with drugmakers and pharmacy benefit managers, Moynihan added.
Employer Coverage Trends
Only 36% of U.S. employers currently cover GLP-1 drugs for both diabetes and weight loss, according to a 2026 survey by the International Foundation of Employee Benefit Plans. This figure has remained flat since 2025, despite rising demand. Some major employers, including PwC, have reportedly stopped covering the drugs for weight loss due to cost concerns.
Healthcare Access Challenges
The high cost of GLP-1 medications—such as Ozempic and Wegovy, which can exceed thousands of dollars per patient annually—has created financial strain for some Americans. Insurance changes have left some patients struggling to afford the drugs, forcing difficult trade-offs between financial stability and physical health.
Bank of America’s Rationale
Moynihan emphasized that the bank’s decision reflects a broader commitment to employee well-being, even if some workers leave before the long-term health benefits materialize. He noted that the company’s healthcare spending has shifted significantly toward GLP-1 drugs, driven by emerging research on their broader health impacts.
Industry Response
Employers nationwide are grappling with soaring demand for GLP-1 medications, which have transformed corporate healthcare budgets. While some companies view the drugs as a long-term investment in workforce health, others have restricted coverage to manage costs. The debate highlights tensions between employee benefits, healthcare affordability, and corporate spending priorities.
Bank of America’s approach underscores the evolving role of employer-sponsored healthcare in addressing chronic conditions like obesity and diabetes, as well as the financial pressures facing businesses balancing innovation with sustainability.